Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1482 Articles

Chris Lange | Jul 8, 2019 at 3:49 PM EDT

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated…

Chris Lange | Jul 1, 2019 at 10:00 AM EDT

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in…

Chris Lange | Jun 29, 2019 at 8:50 AM EDT

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did…

Chris Lange | Jun 26, 2019 at 8:30 AM EDT

Short Sellers Seek Direction on Big Pharma

The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected…

Trey Thoelcke | Jun 26, 2019 at 6:50 AM EDT

The 6 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Intel and Cisco above all other Dow stocks.

Chris Lange | Jun 21, 2019 at 2:40 PM EDT

5 Dow Stocks Not Allowing the DJIA a Proper Rally

Running a screen on Finviz reveals that about two-thirds of the Dow’s 30 components are up by double-digit percentages in…

Lee Jackson | Jun 18, 2019 at 7:57 AM EDT

5 Dividend Leaders To Buy From Merrill Lynch’s Large Cap Defensive Portfolio

Merrill Lynch has many stocks to buy and these are some of its top defensive stocks and dividend stocks that…

Chris Lange | Jun 17, 2019 at 11:56 AM EDT

How Much Is Pfizer Overpaying For Array Bio?

Array BioPharma shares shot up on Monday after the firm announced that it would be acquired by Pfizer in an…

Jon C. Ogg | Jun 14, 2019 at 6:25 AM EDT

7 Stocks Not Enjoying the Bull Market and Holding Down the Dow in 2019

Five of the 30 Dow Jones industrials are down so far in 2019, and some more are literally just one…

Chris Lange | Jun 12, 2019 at 8:30 AM EDT

Big Pharma Sees a Rising Tide in Short Interest

The May 31 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Jun 12, 2019 at 7:15 AM EDT

The 6 Most Shorted Dow Stocks

As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.

Chris Lange | May 28, 2019 at 8:50 AM EDT

Big Pharma Short Sellers Hike Their Bets

The May 15 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | May 28, 2019 at 7:10 AM EDT

Pfizer Overtakes Apple as Most Shorted Dow Stock

As of the most recently reported period, short sellers favored Pfizer, Intel and Apple above all other Dow stocks.

Lee Jackson | May 17, 2019 at 7:05 AM EDT

Merrill Lynch Has 5 Income Portfolio Stocks to Buy With Big-Time Dividends

24/7 Wall St. screened the Merrill Lynch Income Portfolio portfolio looking for high-yielding Buy-rated companies and found the following five…

Chris Lange | May 10, 2019 at 10:15 AM EDT

Big Pharma Scares Off Short Sellers

The April 30 short interest data have been compared with the previous figures, and short interest in most of these…

1 … 27 28 29 30 31 … 99

Pfizer : PFE

All Pfizer Articles

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Short Sellers Seek Direction on Big Pharma

The 6 Most Shorted Dow Stocks

5 Dow Stocks Not Allowing the DJIA a Proper Rally

5 Dividend Leaders To Buy From Merrill Lynch’s Large Cap Defensive Portfolio

How Much Is Pfizer Overpaying For Array Bio?

7 Stocks Not Enjoying the Bull Market and Holding Down the Dow in 2019

Big Pharma Sees a Rising Tide in Short Interest

The 6 Most Shorted Dow Stocks

Big Pharma Short Sellers Hike Their Bets

Pfizer Overtakes Apple as Most Shorted Dow Stock

Merrill Lynch Has 5 Income Portfolio Stocks to Buy With Big-Time Dividends

Big Pharma Scares Off Short Sellers

Why a $2.1 Million 401(k) Holder Is Moving From California to Nevada Before His First RMD at 73

Most Income Investors Have Never Heard of These 3 ETFs Paying Over 10 Percent Monthly

The Home Sale That Adds $5,880 a Year to a Retiree’s Medicare Premium Two Years Later

Why a $2.1 Million 401(k) Holder Is Moving From California to Nevada Before His First RMD at 73

The Home Sale That Adds $5,880 a Year to a Retiree's Medicare Premium Two Years Later

Why a $2.1 Million 401(k) Holder Is Moving From California to Nevada Before His First RMD at 73

Most Income Investors Have Never Heard of These 3 ETFs Paying Over 10 Percent Monthly

Pfizer : PFE

All Pfizer Articles

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Short Sellers Seek Direction on Big Pharma

The 6 Most Shorted Dow Stocks

5 Dow Stocks Not Allowing the DJIA a Proper Rally

5 Dividend Leaders To Buy From Merrill Lynch’s Large Cap Defensive Portfolio

How Much Is Pfizer Overpaying For Array Bio?

7 Stocks Not Enjoying the Bull Market and Holding Down the Dow in 2019

Big Pharma Sees a Rising Tide in Short Interest

The 6 Most Shorted Dow Stocks

Big Pharma Short Sellers Hike Their Bets

Pfizer Overtakes Apple as Most Shorted Dow Stock

Merrill Lynch Has 5 Income Portfolio Stocks to Buy With Big-Time Dividends

Big Pharma Scares Off Short Sellers

Why a $2.1 Million 401(k) Holder Is Moving From California to Nevada Before His First RMD at 73

Most Income Investors Have Never Heard of These 3 ETFs Paying Over 10 Percent Monthly

The Home Sale That Adds $5,880 a Year to a Retiree’s Medicare Premium Two Years Later

Featured Reads

Why a $2.1 Million 401(k) Holder Is Moving From California to Nevada Before His First RMD at 73

The Home Sale That Adds $5,880 a Year to a Retiree's Medicare Premium Two Years Later